Highlights From the American College of Cardiology's 2026 Scientific Sessions

Hear the latest on PCSK9 inhibitors, cardiorenal benefits of GLP-1 drugs, and other clinical research in this interview with Katie Berlacher, MD, MS, chair of this year's annual ACC meeting. Related Content:

• PCSK9 Inhibitors in Diabetes, Tirzepatide's Cardiorenal Effects, Shingles Vaccine, and More From ACC